The ACR Education Exchange 2023 session titled Updates from the Committee on Rheumatology Training & Workforce Issues provided information on fellows-in-training scholarships, Rheumatology Research Foundation awards & more.
Expert Guidance from the ACR/ARP Access in Rheumatology Meeting
Speakers addressed major challenges in coverage and payment facing rheumatology practices, including financial management and obstacles to patient access to treatment.
FDA Commissioner Charts Potential & Challenges of Emerging Technologies in Patient Care
Disparities, representativeness, algorithmic bias, the disruptive emergence of large language models and continued misinformation spread are key issues poised to transform patient care in American healthcare, FDA Commissioner Robert M. Califf, MD, said during a recent event.
Healthcare Insiders Warn of New Technologies’ Impacts on Patient Care
Patient advocates, researcher-clinicians and academic leaders are calling for closer scrutiny of new technologies applied within healthcare, citing concerns about a lack of consideration for how they may affect patient care.
Many Medications: Understanding the Biologic Management of Psoriasis
ORLANDO, FLORIDA — Given the intersection between rheumatology and dermatology for many patients with autoimmune diseases, it’s helpful to hear from specialists in both fields regarding disease management strategies.
The Effect of Upadacitinib on Bone Erosion in Patients with RA
Ho et al. found that upadacitinib may impede the progression of bone erosion in patients with RA. Additionally, bone scans of patients with limited exposure to conventional synthetic disease-modifying antirheumatic drugs showed bone erosion regression, which may result from upadacitinib’s inhibition of Janus kinase 1.
Peresolimab Promising for RA
Stimulating human programmed cell death protein 1 (PD-1), a checkpoint inhibitory receptor, with peresolimab may be a viable way to treat autoimmune diseases, according to a study by Tuttle et al. In the study, patients with active rheumatoid arthritis (RA) who were treated with peresolimab experienced greater improvements in disease activity than those who received placebo.
Sunny San Diego to Welcome ACR Convergence 2023
An in-person poster hall and networking lounges are among the highlights attendees can expect at ACR Convergence 2023 in San Diego, Nov. 10–15.
JAK Inhibitors vs. TNF Inhibitors: Understanding Infection Risks
Research from Choi et al. provides insights into the risk of infection in patients with rheumatoid arthritis (RA), comparing patients treated with Janus kinase inhibitors vs. tumor necrosis inhibitors. The most frequent infection was herpes zoster, with patients treated with JAK inhibitors having a significantly greater risk of herpes zoster infection than those treated with TNF inhibitors.
Point-of-Care Uric Acid Testing
In June 2022, I listened to several presentations on gout at EULAR’s European Congress of Rheumatology. Most began with data confirming a sad truth that we, as rheumatology providers, are all aware of: too many patients are taking subtherapeutic doses of urate-lowering therapy (ULT).1,2 Recommendations from the American College of Physicians in 2017 advocated for…
- « Previous Page
- 1
- …
- 22
- 23
- 24
- 25
- 26
- …
- 103
- Next Page »